According to Dr. Hönle AG's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.51428. At the end of 2023 the company had a P/E ratio of -9.75.
Year | P/E ratio | Change |
---|---|---|
2023 | -9.75 | 46.16% |
2022 | -6.67 | -87.11% |
2021 | -51.8 | -197.75% |
2020 | 52.9 | 141.03% |
2019 | 22.0 | 12.39% |
2018 | 19.5 | 4.77% |
2017 | 18.7 | 8.75% |
2016 | 17.2 | 36.1% |
2015 | 12.6 | -17.2% |
2014 | 15.2 | 49.72% |
2013 | 10.2 | 8.66% |
2012 | 9.36 | 22.12% |
2011 | 7.66 | -1.83% |
2010 | 7.80 | -222.42% |
2009 | -6.38 | -173.86% |
2008 | 8.63 | -39.32% |
2007 | 14.2 | 4.79% |
2006 | 13.6 | -17.83% |
2005 | 16.5 | 6.02% |
2004 | 15.6 | 11.3% |
2003 | 14.0 | -198.25% |
2002 | -14.3 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.